Strides Pharma Science Limited (NSE:STAR)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Pharmaceutical Business (Excl. Bio-Pharmaceutical Business)	48.59B	45.65B	38.90B	36.88B	30.70B
Pharmaceutical Business (Excl. Bio-Pharmaceutical Business) Growth	6.43%	17.36%	5.47%	20.13%	-7.41%
Total	48.59B	45.65B	38.90B	36.88B	30.70B
Total Growth	6.43%	17.36%	5.47%	20.13%	-7.41%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
North America	24.51B	20.67B	19.26B	12.06B
North America Growth	18.55%	7.32%	59.73%	-26.73%
Australia	4.40B	3.65B	3.12B	3.17B
Australia Growth	20.40%	17.18%	-1.86%	29.43%
Africa	4.62B	3.80B	4.51B	5.71B
Africa Growth	21.46%	-15.67%	-21.05%	9.69%
Europe	9.94B	8.66B	8.37B	6.77B
Europe Growth	14.72%	3.50%	23.66%	-7.22%
India	159.56M	234.30M	218.63M	473.47M
India Growth	-31.90%	7.17%	-53.82%	18.15%
Asia (Excluding India)	225.46M	164.67M	460.56M	1.97B
Asia (Excluding India) Growth	36.92%	-64.25%	-76.63%	224.02%
Others	76.43M	116.12M	143.94M	66.78M
Others Growth	-34.18%	-19.33%	115.54%	-27.87%
Unallocated	1.74B	1.60B	807.18M	481.94M
Unallocated Growth	8.46%	98.35%	67.49%	-25.53%
Total	45.65B	38.90B	36.88B	30.70B
Total Growth	17.36%	5.47%	20.13%	-7.41%

Source: S&P Global Market Intelligence.